eLearningClasses.com

Global Multiple Sclerosis Drugs Market 2019-2023 | Evolving Opportunities with Bayer AG and Biogen | Technavio

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Technavio has been monitoring the global multiple sclerosis drugs market since 2014 and the market is poised to grow by USD 7.79 billion during 2019-2023 at a CAGR of close to 6% during the forecast period. Request Free Sample Pages

Read the 110-page research report with TOC on “Multiple Sclerosis Drugs Market Analysis Report by Type (Oral and Parenteral), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 – 2023”.

The market is driven by the rising prevalence of multiple sclerosis. In addition, the development of novel drugs is anticipated to further boost the growth of the multiple sclerosis drugs market.

The diagnosis of multiple sclerosis is increasing due to several factors such as advancement in diagnostic techniques along with growing prevalence of the disease due to genetic and environmental factors. In addition, the rise in autoimmune diseases such as diabetes and infectious mononucleosis further increases the risk of developing multiple sclerosis in patients. Thus, the rising prevalence of multiple sclerosis, especially in Europe is driving the demand for multiple sclerosis drugs.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. View market snapshot before purchasing

Major Five Multiple Sclerosis Drugs Market Companies:

Bayer AG

Bayer AG is headquartered in Germany and operates the business under various segments such as Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. The company offers BETASERON, which is used to treat different forms of multiple sclerosis.

Biogen

Biogen is headquartered in the US and offers products through the business unit, Pharmaceuticals. The company offers Tecfidera to treat relapsing forms of multiple sclerosis. The company also offers AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.

Merck KGaA

Merck KGaA is headquartered in Germany operates under various business segments, namely Healthcare, Life Science, and Performance Materials. The company offers Rebif to treat relapsing forms of multiple sclerosis.

Novartis AG

Novartis AG is headquartered in Switzerland and offers products through the following business segments: Innovative medicines, Sandoz, and Alcon. The company offers GILENYA, which is used to reduce the rate of relapses in relapsing-remitting multiple sclerosis.

Sanofi

Sanofi is headquartered in France and offers products through the following business segments: Pharmaceuticals, Vaccines, and Consumer healthcare. The company offers AUBAGIO and LEMTRADA.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Multiple Sclerosis Drugs Type Outlook (Revenue, USD Million, 2019 – 2023)

  • Oral
  • Parenteral

Multiple Sclerosis Drugs Regional Outlook (Revenue, USD Million, 2019 – 2023)

  • Asia
  • Europe
  • North America
  • ROW

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Amyotrophic Lateral Sclerosis Treatment Market “ Global Amyotrophic Lateral Sclerosis Treatment Market by type (intravenous and oral) and geography (the Americas, APAC, and EMEA).

Atherosclerosis Therapeutics Market “ Global Atherosclerosis Therapeutics Market by product (small molecules and biologics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: https://www.technavio.com